Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD.
Laboratoire d'Immunologie et d'Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064, Saint-Etienne, France.
S
S
Paul
Service de Gastrologie-Entérologie-Hépatologie CIC 1408 INSERM, GIMAP EA3064 CHU, Saint-Etienne, France.
W
W
Dronne
Service de Gastrologie-Entérologie-Hépatologie CIC 1408 INSERM, GIMAP EA3064 CHU, Saint-Etienne, France.
X
X
Roblin
D000068879:Adalimumab; D000328:Adult; D000906:Antibodies / Q000097:blood*; D061067:Antibodies, Monoclonal, Humanized / Q000097:blood / Q000276:immunology*; D005260:Female; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000188:drug therapy* / Q000276:immunology*; D007700:Kinetics; D008297:Male; D012008:Recurrence; D012189:Retrospective Studies; D017211:Treatment Failure
D000906:Antibodies; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab